8月26日 - ** 制药商ImmunityBio IBRX.O股价上涨4.4%，至2.35美元
** 该公司称，早期数据显示，其实验性癌症治疗方案在五名患者身上的测试结果显示了前景
** 公司正在复发性胶质母细胞瘤或脑肿瘤患者中测试其治疗方案
** 公司称，所有五名患者在接受该治疗方案后，疾病控制率达到 100%，该治疗方案还包括公司获准治疗一种膀胱癌的药物 Anktiva。
** 包括本交易日的走势在内，该股今年累计下跌 12.1
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.